Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Pfizer Inc (PFE)

Pfizer Inc (PFE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 149,381,872
  • Shares Outstanding, K 5,666,990
  • Annual Sales, $ 58,496 M
  • Annual Income, $ 2,119 M
  • EBIT $ 10,649 M
  • EBITDA $ 16,939 M
  • 60-Month Beta 0.65
  • Price/Sales 2.55
  • Price/Cash Flow 8.66
  • Price/Book 1.58

Options Overview Details

View History
  • Implied Volatility 24.72% ( -2.82%)
  • Historical Volatility 30.21%
  • IV Percentile 40%
  • IV Rank 45.14%
  • IV High 32.70% on 04/12/24
  • IV Low 18.16% on 05/13/24
  • Put/Call Vol Ratio 0.39
  • Today's Volume 288,063
  • Volume Avg (30-Day) 191,493
  • Put/Call OI Ratio 0.82
  • Today's Open Interest 3,773,732
  • Open Int (30-Day) 3,500,174

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate 0.50
  • Number of Estimates 7
  • High Estimate 0.66
  • Low Estimate 0.38
  • Prior Year 0.10
  • Growth Rate Est. (year over year) +400.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
24.77 +6.40%
on 11/21/24
26.52 -0.60%
on 12/18/24
+1.42 (+5.69%)
since 11/20/24
3-Month
24.48 +7.68%
on 11/15/24
30.43 -13.37%
on 10/09/24
-3.06 (-10.40%)
since 09/20/24
52-Week
24.48 +7.68%
on 11/15/24
31.54 -16.42%
on 07/30/24
-1.27 (-4.60%)
since 12/20/23

Most Recent Stories

More News
Love Dividends? 2 Passive Income Stocks to Scoop Up Now.

These consistent dividend-paying stocks could be a good addition to your portfolio.

ABT : 114.23 (+1.61%)
$SPX : 5,930.85 (+1.09%)
PFE : 26.36 (+2.29%)
Pfizer Just Reassured Investors, but Is the Stock a Buy?

Amid a fall season characterized by restive shareholders seeking an activist bid to unseat senior management and change the trajectory of the company, Pfizer (NYSE: PFE) is communicating that everything...

PFE : 26.36 (+2.29%)
2 Unstoppable Dividend Stocks to Buy If There's a Stock Market Sell-Off

Stock market investors have plenty of reasons to celebrate as 2024 comes to a close. The S&P 500 index set multiple new record highs during the year, delivering a spectacular 25% return year to date amid...

ABBV : 175.58 (+2.37%)
PFE : 26.36 (+2.29%)
The Stock Market Is Historically Pricey: Here's How I'm Positioning My Portfolio for 2025

When things seem too good to be true on Wall Street, they usually are.

COMP : 6.23 (+4.18%)
TDOC : 9.44 (+5.24%)
$NASX : 19,572.60 (+1.03%)
$SPX : 5,930.85 (+1.09%)
$DOWI : 42,840.26 (+1.18%)
PFLT : 10.68 (-0.28%)
PFE : 26.36 (+2.29%)
My Top 10 Stocks to Buy for 2025

It's that time of year again. I'm not referring to buying gifts and preparing holiday meals -- although that may be part of your agenda too. It's time to look back on your portfolio's performance and plan...

NVDA : 134.70 (+3.08%)
VKTX : 42.25 (+1.83%)
CRWD : 362.29 (+3.21%)
ABT : 114.23 (+1.61%)
ETSY : 56.81 (-0.58%)
VRTX : 397.27 (+0.16%)
AXP : 298.65 (+1.90%)
AMZN : 224.92 (+0.73%)
PFE : 26.36 (+2.29%)
PLTR : 80.55 (+8.54%)
Pharma Stock Roundup: PFE's 2025 Outlook, MRK & ABBV's M&A Deals

This week, Pfizer PFE issued its financial guidance for 2025. Sanofi SNY and Teva Pharmaceutical’s TEVA inflammatory bowel disease (IBD) study on their candidate, duvakitug (TEV’574), met its primary...

MRK : 98.05 (-1.48%)
TEVA : 22.09 (+3.66%)
ABBV : 175.58 (+2.37%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)
Bearish Screener Results: Bear Call Spread Opportunities for December 19th

Let’s take a look at Barchart’s Bear Call Spread Screener for December 19th:

BABA : 82.28 (-2.41%)
QCOM : 152.89 (+1.66%)
INTC : 19.52 (+2.41%)
F : 9.88 (+1.44%)
JNJ : 144.47 (+0.62%)
RTX : 116.48 (+0.88%)
PINS : 29.49 (-0.41%)
ADBE : 447.17 (+2.24%)
UBER : 60.73 (+0.86%)
PFE : 26.36 (+2.29%)
Pfizer Could Soar to $36 Per Share, According to a Wall Street Analyst. Is It a Buy at Around $26?

Shares of Pfizer (NYSE: PFE) recently marched higher in response to a dividend payout raise and a forward-looking presentation. Management confirmed the annual revenue and earnings outlook it provided...

PFE : 26.36 (+2.29%)
Pfizer Sparks Analyst Cheer With 2025 Guidance: Retail Maintains Extremely Bullish Stance

Some analysts are optimistic about Pfizer’s potential for growth, especially considering its focus on oncology and recent strategic acquisitions.

XLV : 138.00 (+1.26%)
SCHD : 27.29 (+1.34%)
SPY : 591.15 (+1.20%)
PFE : 26.36 (+2.29%)
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance

Merck MRK announced that the FDA has accepted the biologics license application (BLA) for its investigational prophylactic long-acting monoclonal antibody, clesrovimab (MK-1654), designed to protect infants...

AZN : 65.35 (+1.41%)
MRK : 98.05 (-1.48%)
PFE : 26.36 (+2.29%)
SNY : 47.71 (+0.44%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare...

See More

Key Turning Points

3rd Resistance Point 27.46
2nd Resistance Point 26.97
1st Resistance Point 26.67
Last Price 26.36
1st Support Level 25.88
2nd Support Level 25.39
3rd Support Level 25.09

See More

52-Week High 31.54
Fibonacci 61.8% 28.84
Fibonacci 50% 28.01
Fibonacci 38.2% 27.18
Last Price 26.36
52-Week Low 24.48

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar